The Analysis Of GEMOX Regimen On Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Objective:The purpose of this study is to research on the clinical efficacy and the toxicity of GEMOX regimen on relapsed or refractory aggressive non-Hodgkin’s lymphoma.Method:Retrospectively analyzed thirty-two refractory/relapsing aggressive non-Hodgkin’s Lymphoma patients in the Second Xiangya hospital of Central South University and Hunan province tumor hospital from January2009to January2012. All patients are taken the GEMOX regimen (gemcitabine1000mg/m2on Day1and Day8, oxaliplatin130mg/m2on Day1) every three weeks for one cycle, and it will be evaluated the efficacy in two consecutive cycles. The efficacy evaluation is measured using solid tumor evaluation criteria. Thirty-two patients are analyzed by the indicators such as ORR(objective response rate), the CBR(clinical beneficial rate), PFS(progress free survival), adverse effects rate and so on.Results:Thirty-two patients received a median of4cycles(2to6cycles) the GEMOX chemotherapy, All patients are evaluable for efficacy and adverse effects. Twenty-two ones had response, including that nine had complete response, thirteen had partial response, six had stable disease, and four had progressive disease. The objective response rate was68.8%, the clinical beneficial rate was87.5%, the median of time to progression was8.5months(1.5-12.5months). Eighteen patients with elevation of plasma LDH before treatment, twelve patients plasma LDH returned to normal after treatment, six patients plasma LDH were significantly decreased, but not returned to normal. The mainly adverse effect of chemotherapy toxicity was bone marrow toxicity, the III or IV degree toxic incidence rates of leukocyte and platelets were37.5%and15.6%. Gastrointestinal toxicity was mainly I or II degree,6.3%of patients with III or IV degree gastrointestinal toxicity. There were no obvious heart and hepatorenal harm, no treatment-related death.Conclusion:The GEMOX regimen has a definite efficacy on refractory/relapsing progressive non-Hodgkin’s lymphoma, and all patients can well tolerate it’s adverse effects. It is a further validation of the remedial chemotherapy.